Anti-LMBV single-chain antibody and application thereof in preparation of quantum dot fluorescence immunochromatography test strip
By combining anti-LMBV single-chain antibody with fluorescent quantum dot labeled antibodies, fluorescent quantum dot immunochromatography technology has solved the problems of long detection cycle, low sensitivity and complex operation in the existing technology, and achieved the large mouth black bass iridescent virus Fast, efficient and accurate detection.
Patent Information
- Application Number
- CN202411457247.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-18
AI Technical Summary
The prior art has problems such as long detection cycle, low sensitivity, poor specificity, complex operation, and the need for professional equipment and technicians when detecting largemouth bass iridescent virus (LMBV), which is difficult to meet the needs of fast, efficient and accurate detection.
Develop single-chain antibodies against LMBV bind to fluorescent quantum dot labeled antibodies, and achieve rapid and efficient virus detection through fluorescent quantum dot immunochromatography technology.
It realizes rapid and accurate detection of LMBV, improves the sensitivity and specificity of detection, simplifies operational steps, and is suitable for on-site application and epidemic monitoring.
Smart Images

Figure CN119039426A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biological detection, in particular to an anti-LMBV single-chain antibody and an application thereof in preparing a quantum dot fluorescent immunochromatographic test strip. Background Art
[0002] Largemouth bass (Micropterus salmoides), also known as California bass, is a eurythermal fish native to the Mississippi River Basin in North America. It has become an important freshwater aquaculture species in my country due to its fast growth, low temperature resistance and delicious meat. In 2022, my country's largemouth bass aquaculture volume reached 800,000 tons. However, in recent years, with the continuous increase in aquaculture density and the deterioration of the aquaculture environment, diseases have become a major bottleneck problem in the development of the largemouth bass aquaculture industry, seriously affecting the development of the industry. Among them, Largemouth bass iridovirus disease (LMBVD) is one of the diseases that has attracted attention. Its pathogen is largemouth bass iridovirus (LMBV). After largemouth bass are infected with iridovirus, the mortality rate can reach 70%, which seriously threatens the largemouth bass aquaculture industry. Largemouth bass iridovirus disease has a long incubation period, a fast outbreak speed, a high mortality rate and a wide range of transmission during the aquaculture process. Therefore, it is urgent to establish an efficient virus detection method.
[0003] The main methods for detecting LMBV include pathogen isolation, histological observation, polymerase chain reaction technology (RT-PCR), loop-mediated isothermal amplification technology (LAMP), etc. First, cell isolation of viruses requires cell culture, and the detection cycle requires more than 14 days, with many operations and a long cycle; histological observation can only make a preliminary diagnosis, but cannot confirm the diagnosis; the traditional colloidal gold detection method has low sensitivity, especially when the virus concentration is low, it is difficult to accurately detect the presence of the virus, which may lead to improper disease transmission and control during the breeding process. Secondly, low specificity is also an important issue. LMBV and other viruses may have similar antigenic epitopes, resulting in cross-reactions when antibodies are identified, thereby affecting the accuracy of the test results. In addition, although polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are highly accurate, they usually require professional laboratory equipment and technicians, and the detection process is time-consuming, which is not suitable for rapid identification and control of the initial spread of the epidemic. Due to the serious problem of aerosol pollution, LAMP is mainly used in scientific research and is rarely used in actual sample quarantine. In addition, these methods are limited in operability and convenience in on-site application, especially in situations such as customs quarantine and sudden epidemic monitoring where rapid decision-making is required.
[0004] Immunochromatography technology relies on the interaction between specific antibodies and antigens, and achieves qualitative and quantitative detection of antigens through chromatography. However, traditional immunochromatography often faces challenges in the preparation of chromatographic materials and antibody specificity, resulting in inaccurate test results. Fluorescent labeling technology uses fluorescent substances to label antibodies or antigens, and uses fluorescent signals to indicate the presence and quantity of target molecules. Although it can provide intuitive fluorescent signals, the stability of fluorescent substances, luminescence intensity, and quantitative analysis capabilities of fluorescent signals are also important factors that limit its widespread application. There have been related reports on the combined application of these two technologies in the field of virus detection, but most methods have problems such as low sensitivity, low specificity, or complex operation. Especially when detecting viruses with complex characteristics such as largemouth bass iridovirus, current detection technologies often fail to meet the needs of fast, efficient, and accurate detection.
[0005] The selection of antibodies is the core of preparing immunochromatographic test strips. At present, the antibodies used in commercial test strips are all monoclonal antibodies, and the high cost and long production cycle of monoclonal antibodies greatly limit their application in aquatic animals. These problems and defects limit the application effect of existing technologies in LMBV detection. Therefore, it is an urgent need to develop a fast, efficient, economical, highly specific and easy-to-operate virus detection method. Summary of the invention
[0006] The purpose of the present invention is to provide a single-chain antibody against LMBV and its application in the preparation of quantum dot fluorescent immunochromatographic test strips to solve the problems existing in the above-mentioned prior art. The present invention utilizes the means of fluorescent quantum dot immunochromatographic technology and realizes rapid and efficient detection of LMBV by combining a highly specific single-chain antibody against largemouth bass LMBV with an antibody labeled with fluorescent quantum dots.
[0007] To achieve the above object, the present invention provides the following solutions:
[0008] The present invention provides a single-chain antibody against largemouth bass iris virus. The single-chain antibody comprises Ab-K1 or Ab-K2. The amino acid sequence of Ab-K1 is shown in SEQ ID NO.11, and the amino acid sequence of Ab-K2 is shown in SEQ ID NO.12.
[0009] The present invention also provides a fluorescent quantum dot-labeled antibody against largemouth bass iridovirus, wherein the fluorescent quantum dot-labeled antibody comprises the single-chain antibody.
[0010] The present invention also provides the use of the single-chain antibody or the fluorescent quantum dot-labeled antibody in preparing a product for detecting largemouth bass iridovirus.
[0011] Furthermore, the products include test strips and test kits.
[0012] Furthermore, the test strip includes a quantum dot fluorescent immunochromatography test strip.
[0013] The present invention also provides a quantum dot fluorescent immunochromatographic test strip for detecting largemouth bass iridovirus, comprising a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, wherein the nitrocellulose membrane comprises a detection line and a quality control line, and the detection line comprises the fluorescent quantum dot-labeled antibody.
[0014] Furthermore, the quality control line includes goat anti-rabbit IgG antibody.
[0015] Furthermore, when the quantum dot fluorescent immunochromatographic test strip is used, the virus titer in the sample to be tested is ≥10 2 TCID 50 / mL.
[0016] Furthermore, the amount of the sample to be tested dripped onto the quantum dot fluorescent immunochromatographic test strip is 100 μL.
[0017] Furthermore, the reaction time of the sample to be tested in the quantum dot fluorescent immunochromatographic test strip is 20 minutes.
[0018] The present invention discloses the following technical effects:
[0019] The present invention uses spleen tissue of New Zealand white rabbits infected with LMBV to construct a phage antibody library, and obtains two high-affinity single-chain antibody proteins Ab-K1 and Ab-K2 through 5 rounds of bio-panning combined with phage ELISA and gene sequencing. When the dilution ratio of the two single-chain antibody proteins Ab-K1 and Ab-K2 is 1:3200, they still have affinity with LMBV virus particles, and when the dilution ratio of the single-chain antibody protein Ab-K1 is 1:6400, it still has affinity with LMBV virus particles.
[0020] The present invention utilizes fluorescent quantum dot immunochromatography technology to achieve rapid and efficient detection of LMBV by combining highly specific anti-largemouth bass LMBV single-chain antibodies with antibodies labeled with fluorescent quantum dots. Specifically, the highly specific antibodies used in the present invention can accurately identify and bind to the iridovirus in the sample to be tested, thereby ensuring the accuracy of the detection. At the same time, the antibodies labeled with fluorescent quantum dots not only have good fluorescence properties, making the fluorescent signal easy to observe and detect, but also have a large specific surface area, which can bind to more virus molecules, thereby improving the sensitivity of the detection. This process not only improves the accuracy and sensitivity of the detection, but also simplifies the operating steps, providing strong technical support for the detection and prevention of iridoviruses. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 This is a graph of serum antibody titers of New Zealand white rabbits immunized with iridovirus. The data are expressed as mean ± standard deviation.
[0023] Figure 2 It is the antibody VL gene map amplified by light chain primers, where lane M1 is DL2000 Plus DNAMarker, and lanes 1-4 are light chain gene VL (1-4);
[0024] Figure 3 It is the antibody VH gene map amplified by heavy chain primers, where lane M1 is DL2000 Plus DNAMarker, and lanes 1-6 are heavy chain gene VH (1-3);
[0025] Figure 4 It is the splicing map of scFv gene, wherein lane M1 is DL2000 Plus DNAMarker, and lanes 1-6 are scFv gene scFv (1-6);
[0026] Figure 5 The figure is the result of double enzyme digestion identification of pCANTAB5E-scFv recombinant plasmid, wherein lane M1 is DL2000 Plus DNA Marker, lanes 1 and 2 are undigested recombinant plasmids, and lanes 3 and 4 are double enzyme digested recombinant plasmids;
[0027] Figure 6 This is a graph for the validation of the recombination rate of the antibody library, where lane M1 is DL2000 Plus DNAMarker, and lanes 1-18 are bacterial liquid PCR of different monoclonal phages;
[0028] Figure 7 This is a graph for the validation of the recombination rate of the antibody library, where lane M1 is DL2000 Plus DNAMarker, and lanes 19-32 are bacterial liquid PCR of different monoclonal phages;
[0029] Figure 8 This is the Phage-ELISA antibody affinity test, where the horizontal axis is 1-48 positive clones and negative controls; the vertical axis is OD 450 value;
[0030] Fig. 9The SDS-PAGE analysis diagram of the antibody protein Ab-K1, wherein lane M is the protein relative molecular mass standard, lane 1 is the pET28a empty protein, lane 2 is the purified Ab-K1 protein, and lane 3 is the unpurified Ab-K1 protein;
[0031] Fig.10 The SDS-PAGE analysis diagram of the antibody protein Ab-K2, wherein lane M is the protein relative molecular mass standard, lane 1 is the pET28a empty protein, lane 2 is the unpurified Ab-K2 protein lane, and lane 3 is the purified Ab-K2 protein;
[0032] Fig.11 Graphs showing affinity analysis of antibody proteins Ab-K1 and Ab-K2 with LMBV, respectively, wherein K1 represents antibody protein Ab-K1, and K2 represents antibody protein Ab-K2;
[0033] Fig.12 Schematic diagram of the preparation of quantum dot microspheres;
[0034] Fig.13 This is a schematic diagram of the assembly and detection process of the quantum dot flow immunoassay strip;
[0035] Fig.14 The preliminary test results of the test strips, a is the reaction under visible light, b is the result under a fluorescence reader with an excitation wavelength of 365nm;
[0036] Fig.15 is the specific detection result of the immunochromatographic test strip based on JY-Q@K1, and N is the PBS control group;
[0037] Fig.16 is the sensitivity test result of the immunochromatographic test strip based on JY-Q@K1, and N is the PBS control group;
[0038] Fig.17 is the test result of clinical samples based on JY-Q@K1 immunochromatographic test strip, and N is the PBS control group. DETAILED DESCRIPTION
[0039] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0040] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0041] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0042] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0043] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0044] Example 1 Construction of anti-LMBV rabbit-derived single-chain antibody library
[0045] 1. Polyclonal Antibody Preparation
[0046] 1.1 Animal immunization
[0047] The virus concentration was 10 7 TCID 50 / mL of LMBV-FS001 strain (LMBV-FS001 strain is disclosed in the Chinese patent with application number 202310757360.5 and invention name "A mRNA vaccine for aquaculture and its preparation method") was used as an immunogen, and New Zealand white rabbits were immunized in the form of multiple booster immunizations, for a total of four immunizations. For the first immunization, the LMBV virus liquid was emulsified with an equal amount of complete Freund's adjuvant as an immunogen, and for the booster immunization, the LMBV virus liquid was emulsified with an equal amount of incomplete Freund's adjuvant as an immunogen.
[0048] 1.2 Antibody titer detection
[0049] When determining the serum specific antibody titer, LMBV was used as the antigen, the collected serum was the test serum, mouse anti-rabbit IgM monoclonal antibody was used as the primary antibody, and the dilution ratio was 1:2000; HRP goat anti-mouse IgG monoclonal antibody was used as the secondary antibody, and the dilution ratio was 1:4000. The antibody titer in the serum was determined by enzyme-linked immunosorbent assay. After color development, the absorbance at a wavelength of 450nm was measured by an enzyme marker. The results are as follows: Figure 1 As shown, after the fourth booster immunization, the serum antibody titer reached the highest level, reaching above 1:25,600, indicating that polyclonal antibodies with higher titers were prepared using LMBV as the immunogen, which can meet the needs of library construction.
[0050] 1.3 Polyclonal Antibody Collection
[0051] After the immunization, the New Zealand white rabbits were anesthetized with ether, blood was collected from the heart, and serum was stored in a -20°C refrigerator for later use. The spleen was then collected and cut into small pieces, packed in 10 mL centrifuge tubes, immersed in Trizol, and stored in a -80°C refrigerator for later use.
[0052] 2. Construction of single-chain antibody library
[0053] 2.1 Antibody variable region gene primer design
[0054] The immunoglobulin sequence information mainly based on New Zealand white rabbits was retrieved in NCBI and IMGT, and the degenerate primers of the antibody heavy chain VH and light chain VL were designed respectively by the primer design software Primer5.0 according to the relatively conservative gene framework region (FR region) in the antibody variable region and the degenerate primer design rules, including four upstream amplification primers and one downstream amplification primer for the light chain; one upstream amplification primer and three downstream amplification primers for the heavy chain, namely Sfi I-VL-FP (1-4), VL-RP0-Linker and Linker-VH-FP0, VH-RP (1-3)-Not I. In order to splice the heavy chain and light chain of the antibody into a complete single-chain antibody structure, a flexible peptide Linker is used for connection, and the amino acid sequence of Linker is GGGGSGGGGSGGGGS (SEQ ID NO.1). According to the restriction enzyme sites on the connection vector pCANTAB-5E, Sfi I restriction enzyme site and Not I restriction enzyme site and protective bases were added to the upstream primer of the heavy chain and the downstream primer of the light chain, respectively. The specific sequences of the amplification primers are shown in Tables 1 and 2.
[0055] Table 1 Antibody light chain VL amplification primers
[0056]
[0057]
[0058] Note: The underlined part indicates the restriction site, and the bold part indicates the VL sequence.
[0059] Table 2 Antibody heavy chain VH amplification primers
[0060]
[0061] Note: The underlined part indicates the restriction site, and the bold part indicates the VH sequence.
[0062] 2.2 RNA extraction and inversion
[0063] About 50 mg of spleen tissue was placed in a 1.5 mL centrifuge tube to extract RNA. The Q RT SuperMix for qPCR kit uses a two-step method to synthesize cDNA. First, add 8.0μL RNase free ddH2O, 4.0μL 4×gDNAwiper Mix, and 4.0μL template RNA to an RNase free centrifuge tube, gently pipette to mix, and react at 42°C for 2 minutes. Then, add 4.0μL 5×qRTSuperMixⅡ to the reaction tube in the first step, gently mix, react at 50°C for 15 minutes, and react at 85°C for 2 minutes to obtain cDNA. The obtained cDNA was stored at -20°C for later use.
[0064] 2.3 PCR amplification of light chain VL and heavy chain VH genes
[0065] The reverse transcribed cDNA was used as a template and the designed primers were used to amplify the antibody light chain VL and heavy chain VH, respectively. The amplified products were named VL1, VL2, VL3, VL4 and VH1, VH2, VH3, respectively.
[0066] PCR amplification reaction conditions: 95℃ pre-denaturation for 5min; 95℃ denaturation for 30s, 56℃ annealing for 30s, 72℃ extension for 30s, 36 cycles; 72℃ extension for 10min. The PCR product was identified by agarose gel electrophoresis, electrophoresis conditions: 120V constant voltage for 20min. The results are as follows Figure 2 and Figure 3 As shown, the target band sizes were all between 250 bp and 500 bp, approximately 330 bp, which was consistent with the theoretical size of the expected product, proving that the VL and VH genes were successfully amplified.
[0067] 2.4 Splicing of single-chain antibody genes
[0068] The amplified product of the previous step was recovered using a purification recovery kit, and the recovered heavy and light chain genes (VL1, VL2, VL3, VL4 and VH1, VH2, VH3) were used as templates to perform overlap extension PCR using the light chain upstream and heavy chain downstream primers to splice into a complete single-chain antibody scFv. The spliced product was tested by nucleic acid electrophoresis and recovered by gel cutting. The results of nucleic acid electrophoresis detection are shown in Figure 2. Figure 4 As shown, the size of the scFv gene fragment ranges from 500 bp to 750 bp, with a size of approximately 700 bp, which is consistent with the expected theoretical product size of scFv splicing.
[0069] PCR amplification reaction conditions: Step 1: pre-denaturation at 95°C for 5 min; denaturation at 95°C for 15 s, annealing at 56°C for 15 s, extension at 72°C for 30 s, 7 cycles; extension at 72°C for 5 min; Step 2: pre-denaturation at 95°C for 5 min; denaturation at 95°C for 15 s, annealing at 56°C for 15 s, extension at 72°C for 30 s, 21 cycles; extension at 72°C for 5 min.
[0070] 3. Construction of single-chain antibody library
[0071] 3.1 Construction of recombinant plasmid pCantab5E-Ab
[0072] First, ScFv and pCANTAB 5E were digested with NotI at 37℃ for 10h, and then digested with SfiI at 50℃ for 5h. After the digestion, ligation was performed, and the digestion products and ligation products were analyzed by agarose gel electrophoresis. The double digestion results showed that the recombinant plasmid pCANTAB 5E-ScFv was successfully constructed ( Figure 5 ), and the digestion product was purified and recovered using a gel recovery kit. The purified and recovered product was ligated at 16°C overnight and transformed into Escherichia coli (E. coli) TG1 competent cells. The transformation was repeated 25 times to obtain a library capacity of 3.6×10 6 pfu / mL of the original bacterial solution of the LMBV primary antibody library.
[0073] 3.2 Construction and identification of phage library
[0074] Randomly pick 32 single colonies with good growth from the plate and place them in 500 μL 2×YT-A medium. After shaking and culturing, use them as templates for bacterial liquid PCR. Calculate the recombination rate of the antibody library as follows: Figure 6 and Figure 7 As shown, 30 of the 32 single colonies contained scFv genes, indicating positive antibodies; the PCR results of single colonies 26 and 27 showed no obvious bands, indicating that the recombination rate of the antibody library was 30 / 32≈93.75%.
[0075] The remaining culture after transformation was inoculated into 100 mL 2×YT-Amp liquid medium (AMP concentration 50 μg / mL), 1 / 5 volume of 25% glucose stock solution was added, and the culture was cultured at 37°C and 180 rpm for 4 h. Then, helper phage M13K07 was added, and the culture was incubated at 37°C for 1 h, then cultured at 180 rpm for 2 h. The supernatant was discarded after centrifugation at 5000 rpm for 15 min, and the precipitate was resuspended with 100 mL 2×YT-Amp-Kan liquid medium (AMP and KAN concentration 50 μg / mL), cultured on a shaking table overnight, centrifuged at 4°C and 10000 rpm for 20 min, the supernatant was transferred to a 50 mL centrifuge tube, 1 / 5 volume of PEG / NaCl was added, and the culture was allowed to stand on ice for 1 h, then centrifuged at 4°C and 12000 rpm for 30 min, the supernatant was discarded, and the residual supernatant was removed by centrifugation again. Add 150 μL PBS to each tube to resuspend the precipitate, collect and centrifuge for 10 min, and the supernatant is the primary phage single-chain antibody library, which is stored at 4°C for later use. After assembly with helper phage M13K07, the titer of the constructed phage scFv antibody library is 2.1×10 11 pfu / mL, which meets the requirements for subsequent bio-panning of phage libraries and should be immediately bio-panning.
[0076] Example 2 Screening, identification and prokaryotic expression of anti-LMBV single-chain antibody
[0077] 1. Biopanning of anti-LMBV phage display antibody library
[0078] 10 7 TCID 50 After diluting LMBV / mL 10 times, 100 μL / well was added to the ELISA plate (three replicates each time), and coated overnight at 4°C; washed with PBS 3 times, 5 min each time, 5% skim milk powder was added to block the solid phase carrier at 100 μL / well, and blocked at 37°C for 2 h. After washing with PBS, 100 μL of phage library was added to each well and incubated at 37°C for 2 h; after washing with PBST, 100 μL of Gly-HCl elution buffer was added, and the plates were incubated at 37°C for 60 rp. After incubation with slow shaking for 10 min, the eluate was aspirated into a centrifuge tube and 100 μL of Tris-HCl with a pH of 7.4 was immediately added to neutralize the eluate (to maintain the infection ability of the phage); 500 μL of overnight cultured TG1 was added to the eluate and cultured at 37°C for 4 h; the eluted buffer was diluted and spread on the plate, the number of colonies was calculated, and the remaining eluate was saved for the next round of panning. The panning operation was repeated for five rounds, and the phage output in the first round was 1.3×10 5 pfu / mL, and the phage output in the fifth round was 1.3×10 8 pfu / mL, the specific phage output was greatly improved; the phage output ratio increased from 4.6×10 -5Increased to 4.8×10 -4 The enrichment factor was 104 times, which indicated that specific phages binding to LMBV antigens were effectively enriched.
[0079] 2. Positive clone screening
[0080] After 5 rounds of panning, 48 different monoclonal colonies were randomly selected to prepare phage supernatants, and then the affinity of phage single-chain antibody to LMBV was determined by enzyme-linked immunosorbent assay using LMBV virus liquid as antigen, phage amplification product as test antibody, and anti-M13 monoclonal antibody as binding antibody at a dilution ratio of 1:2000. 450 A positive phage clone was defined as one with a value greater than 2 times that of the negative control (NC). Figure 8 As shown, among the 48 monoclonal colonies, 43 monoclonal colonies had an OD of 450 The ratio of the value to the NC value was greater than 2.0, indicating a positive clone. The positive rate of the recombinant phage was 43 / 48 = 89.58%.
[0081] According to the above affinity test results, the 10 positive phages with the highest affinity were sequenced to detect the insertion of antibody genes in each monoclonal colony. By comparing and analyzing the sequencing results, it was found that the antibody sequences of 4 positive phages were exactly the same, and the actual size of their DNA was 687bp. The antibody was named Ab-K1, and the antibody sequences of 2 positive phages were the same, and the actual size of their DNA was 714bp, named Ab-K2; the other two were pure heavy chain antibody sequences, named Ab-K3 and Ab-K4, respectively, and the results are shown in Table 3.
[0082] Table 3 Ab-S1 and Ab-S2 amino acid sequences
[0083]
[0084]
[0085] Note: The bold part in the table represents the Linker sequence.
[0086] 3. Synthesis and prokaryotic expression of single-chain antibody gene recombinant expression plasmid
[0087] The 6 scFv strains obtained by bio-panning were expressed in prokaryotes, and the target genes were connected to the pMD19-T vector and amplified in large quantities. The amplified target genes were then connected to the expression vector PET-28a and transformed into Escherichia coli for prokaryotic expression. The expressed ScFv mainly existed in the bacteria in the form of inclusion bodies. After fragmentation, protein denaturation, nickel affinity column purification, renaturation, and lyophilization, the antibody recombinant proteins Ab-K1 and Ab-K2 were obtained. The SDS-PAGE results are shown in Figure 2. Fig. 9 , Fig.10 As shown, the sizes of antibody proteins Ab-K1 and Ab-K2 were both about 40 kDa, which was consistent with the expected results. The expressed proteins could be recognized by anti-His monoclonal antibodies, indicating that the antibody proteins were successfully expressed in E. coli.
[0088] 4. Antibody protein affinity detection
[0089] The affinity of pET28a-scFv to LMBV virus particles was detected by ELISA. The freeze-dried protein powder was dissolved in PBS buffer to prepare the dilution stock solution. The antibody dilution ratio was 1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, and 1:12800. The antigen used in this method is LMBV virus liquid, the diluted antibody is purified protein, the primary antibody is mouse anti-6×His monoclonal antibody, and the secondary antibody is HRP-labeled goat anti-mouse IgG. Finally, TMB single-component colorimetric solution was used for color development, and the OD value was measured at a wavelength of 450nm. The results are as follows: Fig.11 As shown, with the increase of the dilution multiple, the affinity of the two antibody proteins to the LMBV virus particles gradually decreased. When the dilution ratio was 1:3200, Ab-K2 still had affinity with LMBV. When the dilution ratio was 1:6400, Ab-K1 still had affinity with LMBV. The overall affinity of Ab-K1 was also higher than that of Ab-K2. Therefore, Ab-K1 was selected as the antibody marker in the subsequent test strips.
[0090] Example 3 Establishment and Optimization of Quantum Dot Immunochromatography Technology
[0091] 1. Antibody-labeled fluorescent quantum dot microspheres
[0092] The screened highly specific anti-LMBV single-chain antibodies were coupled with carboxylated quantum dots using the activated ester method. 0.15 mg of quantum dot microspheres (QBs, Wuhan Jiayuan Quantum Dot Technology Development Co., Ltd., fluorescence emission wavelength of 365 nm) were added to 0.75 mL of phosphate buffer solution PB (0.01 mol / L, pH 6.0), diluted to 0.1 mg / mL, ultrasonicated for 3 min, and added with a freshly prepared 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, Sigma, USA) solution with a final concentration of 10 μg / mg. The mixture was activated in a shaker at 37 °C and 120 r / min for 15 min to obtain carboxylated QBs (10 mg mL -1 ). 0.25 g of K1 (Ab-K1) was added to 100 mL of deionized water to prepare a K1 solution, and 0.2 mL of the prepared carboxylated QBs (10 mg mL -1 ) were dispersed in K1 solution, ultrasonicated for 30 min, and finally BSA with a final concentration of 1% was added. The reaction was blocked in a shaker at 37°C and 120 r / min for 1 h. After the reaction was completed, the mixture was centrifuged at 12000 r / min for 15 min, and the supernatant was discarded. The process was repeated twice to ensure the complete adsorption of QBs on the surface of K1. Finally, the mixture was centrifuged (6000 rpm, 6 min), and the precipitate was resuspended in 10 mL of ethanol to prepare antibody-labeled quantum dot microspheres (K1-QBs). The schematic diagram of the preparation of quantum dot microspheres is shown in the figure. Fig.12 shown.
[0093] 2. Characterization of quantum dot microspheres
[0094] Transmission electron microscopy (TEM) and high-resolution transmission electron microscopy (HRTEM) were used to analyze and characterize the morphology and dispersibility of the synthesized JY-Q and JY-Q@K1 nanocomposites. Zeta potential analyzer was used to determine their potential. The prepared JY-Q@K1 suspension was irradiated with visible light and ultraviolet light (365nm), and the images were recorded and their fluorescence properties were analyzed.
[0095] 3. Preparation of immunochromatographic test strips
[0096] The immunochromatographic test strip consists of four independent parts: sample pad, conjugate pad, nitrocellulose (NC) membrane and absorption pad. Rabbit anti-LMBV single-chain antibody and goat anti-rabbit IgG antibody were sprayed onto the NC membrane at the same time to construct the detection line and quality control line respectively, with a distribution rate of 0.1 μL / mm. The prepared NC membrane was dried in a constant temperature drying oven at 37°C for 2 hours. Subsequently, the sample pad, conjugate pad, NC membrane and absorption pad were assembled onto a plastic backing card, and the test strip detection process was as follows Fig.13Finally, the prepared test strips were placed in a plastic box and stored with a desiccant at room temperature. The fluorescence intensity on the test line was read with a fluorescence reader (excitation wavelength was 365 nm).
[0097] 4. Preliminary testing of test strip performance
[0098] The prepared test strip was inserted into the PBS buffer containing LMBV virus. The solution moved to the absorption pad by capillary force. The LMBV in the solution quickly combined with the antibody-modified JY-Q@K1 to form a JY-Q@K1-LMBV complex, which was recognized and bound by the LMBV antibody at the T line of the NC membrane. The excess immune JY-Q@K1 continued to move forward and was fixed on the control line of the test strip. After the assembled test strip was restored to room temperature, PBS diluent and virus concentration of 10 were added respectively. 6 TCID 50 / mL of LMBV were tested with 100 μL each. Finally, the fluorescence intensity on the test line was read with a fluorescence reader (excitation wavelength was 365 nm). The results were as follows Fig.14 As shown, the K1 antibody protein has detection activity (only the C line in the control group showed color, and both the T and C lines in the experimental group showed color), and can be used to prepare LMBV immunochromatographic test strips for the detection of LMBV.
[0099] 5. Optimization of the immune JY-Q@K1 test strip
[0100] To further optimize the quantum dot immunochromatography, the NC membrane, buffer, optimal reaction time, antibody spraying concentration and other factors were optimized. Under the optimized buffer system, the largemouth bass iridovirus LMBV was diluted with buffer gradients in the concentration range of 10 7 -10CFU·mL -1 The test strip was then inserted into 100 μL of sample buffer to move the antigen binding label to the absorbent pad by capillary action. After 10 min of chromatography reaction, the fluorescence signal on the test line was recorded using a fluorescence reader (365 nm excitation), and each test line was read three times.
[0101] 5.1 Specificity detection
[0102] To evaluate the specificity of the detection method, six test strips were taken and tested with five common fish viruses stored in the laboratory: infectious hematopoietic necrosis virus (IHNV), largemouth bass rhabdovirus (MSRV), spring carp virus (SVCV), grass carp reovirus (GCRV) and largemouth bass iridovirus (LMBV). After incubation, they were diluted to 10 6 TCID 50 / mL, add 100μL to each sample well, let it stand for 20min, and observe the test results. Verify the specificity of the prepared fluorescent LFIA strip. The results are as follows Fig.15 As shown, it shows that the LMBV detected by this test strip is positive, and the others are negative (only the two lines of LMBV are colored, and the others are C lines), so it can be seen that the test strip has good specificity.
[0103] 5.2 Sensitivity test
[0104] LMBV virus (concentration 10 7 TCID 50 / mL) were diluted to 10 6 TCID50 / mL, 10 5 TCID 50 / mL, 10 4 TCID 50 / mL, 10 3 TCID 50 / mL, 10 2 TCID 50 / mL, 10TCID 50 / mL, take seven test strips from the same batch to test their sensitivity. Before testing, balance the sample to be tested to room temperature, use a pipette to take 100μL of each dilution sample and slowly drip it vertically on the sample pad of the test strip (take the test strips prepared from the same batch to reduce the influence of errors), and observe the test results after 20 minutes. The results are as follows Fig.16 It showed that LMBV cell culture was only viable at a concentration of 10 TCID 50 / mL, the test result is negative; when the concentration is 10 6 TCID 50 / mL~10 2 TCID 50 / mL, the test result is positive. Therefore, this test strip is positive when the virus concentration is ≥10 2 TCID 50 LMBV can be effectively detected when the concentration is 1.0447 W / mL.
[0105] 5.3 Stability test
[0106] Sixteen LMBV quantum dot immunochromatographic test strips of the same batch were prepared, placed in a desiccant, and stored in a refrigerator at 4°C. Four test strips were taken out at 1, 2, 3, and 6 months after storage, of which three were prepared at a concentration of 10 6 TCID 50 / mL LMBV was used as a sample for testing, and another sample was tested with PBS buffer as a sample (negative control). The stability of the test strip was determined by detecting the change in the sensitivity of the test strip. The test results showed that: 4 test strips with PBS buffer as samples had only C line color, and T line did not color, indicating that the test strip had no quality problems; 12 test strips with virus liquid as samples had both C line and T line color, indicating that the test strip had good repeatability.
[0107] 5.4 Clinical sample testing
[0108] Inject 20 μL of virus at a concentration of 10 6 TCID 50 / mL of LMBV was injected into the bodies of 50-day-old largemouth bass. When the largemouth bass was dying, the body mucus, liver, gills, and intestines were taken to make tissue suspensions (1 mg of tissue was added to 100 μL of 0.01M PBS buffer to lyse the tissue). Then, test strips made in the same batch were used to test the virus in the tissue suspensions. Based on the test results, the universality of the test strips was analyzed. Fig.17 The results showed that LMBV could be detected in the intestinal tissue suspension of largemouth bass infected with LMBV.
[0109] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A single-chain antibody against largemouth bass iridovirus, characterized in that: The single-chain antibody includes Ab-K1 or Ab-K2, the amino acid sequence of Ab-K1 is shown as SEQ ID NO.11, and the amino acid sequence of Ab-K2 is shown as SEQ ID NO.
12.
2. A fluorescent quantum dot-labeled antibody against largemouth bass iridovirus, characterized in that: The fluorescent quantum dot-labeled antibody comprises the single-chain antibody according to claim 1.
3. Use of the single-chain antibody according to claim 1 or the fluorescent quantum dot-labeled antibody according to claim 2 in the preparation of a product for detecting largemouth bass iridovirus.
4. The use according to claim 3, characterized in that: The products include test strips and test kits.
5. The use according to claim 4, characterized in that: The test strips include quantum dot fluorescent immunochromatography test strips.
6. A quantum dot fluorescent immunochromatographic test strip for detecting largemouth bass iridovirus, characterized in that: It comprises a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, wherein the nitrocellulose membrane comprises a detection line and a quality control line, and the detection line comprises the fluorescent quantum dot-labeled antibody according to claim 2.
7. The quantum dot fluorescent immunochromatographic test strip according to claim 6, characterized in that: The quality control line includes goat anti-rabbit IgG antibody.
8. The quantum dot fluorescent immunochromatographic test strip according to claim 6, characterized in that: When the quantum dot fluorescent immunochromatographic test strip is used, the virus titer in the sample to be tested is ≥10 2 TCID 50 / mL.
9. The quantum dot fluorescent immunochromatographic test strip according to claim 8, characterized in that: The amount of the sample to be tested dripped onto the quantum dot fluorescent immunochromatographic test strip is 100 μL.
10. The quantum dot fluorescent immunochromatographic test strip according to claim 8, characterized in that: The reaction time of the sample to be tested in the quantum dot fluorescent immunochromatographic test strip is 20 minutes.
Citation Information
Patent Citations
Micropterus salmoides iridovirus antibody colloidal gold test strip as well as preparation method and application thereof
CN116840463A
Single-chain antibody protein for resisting iridovirus of micropterus salmoides as well as screening method and application of single-chain antibody protein
CN118324901A
